TICKERNERD
Menu
CHECHEHealthcare · Medical Care Facilities

CHE Stock Forecast: Chemed Corp. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$524
+0.09% on the day

The 4 Wall Street analysts covering Chemed Corp. hold a median 12-month price target of $549 — +4.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 2 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$6.7B
Ticker Nerd rank
89 / 100
Median analyst target
$549
Analysts covering
4
Revenue$657.5M+1.6% y/y
Operating income$84.6M
Net income$66.3M
Free cash flow$71.1M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.8%
1M
−2.9%
YTD
+23.1%
1Y
+14.7%
From 52W high
−5.0%
From 52W low
+42.7%
$368
$552
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CHE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Chemed Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
89 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
96
Volatility
91
Quality
84
Accruals
73
Value
68
Momentum
68
Issuance
56
Growth
51
Size
19

Revisions (96): Analysts have, on balance, been raising their forecasts.

Growth (51): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (19): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CHE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CHE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$400$450$500$550$600Oct 25Jan 26Apr 26Jul 26CHEHigh $590Median $549Low $520

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
1 Buy3 Hold0 Sell
Low $520Median $549High $590

The green dot is the last close — the median target sits +4.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
31 July 2026OppenheimerMaintainsOutperform$500 → $590
30 July 2026RBC CapitalMaintainsSector Perform$436 → $548
9 July 2026B of A SecuritiesMaintainsNeutral$450 → $510
9 July 2026B of A SecuritiesMaintainsNeutral—
27 Apr 2026RBC CapitalMaintainsSector Perform—
27 Feb 2026OppenheimerMaintainsOutperform—
27 Feb 2026RBC CapitalDowngradeSector Perform—
22 Jan 2026JefferiesDowngradeHold—
10 Nov 2025RBC CapitalMaintainsOutperform—
10 Sept 2025B of A SecuritiesMaintainsBuy—
2 Sept 2025JefferiesUpgradeBuy—
31 July 2025OppenheimerMaintainsOutperform—
31 July 2025RBC CapitalMaintainsOutperform—
25 July 2025JefferiesInitiatesHold—
30 June 2025B of A SecuritiesMaintainsBuy—
30 June 2025RBC CapitalMaintainsOutperform—
28 Apr 2025RBC CapitalMaintainsOutperform—
14 Mar 2025RBC CapitalMaintainsOutperform—
5 Nov 2024RBC CapitalMaintainsOutperform—
21 May 2024RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CHE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CHE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, Chemed Corp. returned +14.7% against +21.4% for the S&P 500, dividends included.

CHE vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Oct 25Jan 26Apr 26Jul 26CHES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CHE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+4.8%
Analysts raising
4
Analysts cutting
0
Fundamentals

Chemed Corp. (CHE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
25.9×

Cheaper than 30% of US stocks

Price / sales
2.6×

Cheaper than 46% of US stocks

Price / book
8.1×

Cheaper than 13% of US stocks

EV / EBITDA
16.8×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
8.8%

Higher than 49% of US stocks

Earnings growth (YoY)
29.0%

Higher than 65% of US stocks

Gross margin
32.8%

Higher than 39% of US stocks

Operating margin
13.3%

Higher than 70% of US stocks

Net margin
10.6%

Higher than 71% of US stocks

Returns & dividend
Return on equity
27.1%

Higher than 86% of US stocks

Return on assets
13.5%

Higher than 96% of US stocks

Dividend yield
0.5%

Higher than 10% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Chemed Corp. (CHE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Chemed Corp. has a market value of $6.7B and an enterprise value of $7.0B.

  • Revenue in the twelve months to 31 Mar 2026: $2.5B. The latest quarter grew 8.8% year on year.

  • Net income over the same four quarters: $259.8M, a 10.2% net margin.

  • Diluted earnings per share, trailing twelve months: $18.35.

  • Free cash flow in the twelve months to 31 Mar 2026: $377.1M, after $50.5M of capital spending.

  • Chemed Corp. spent $588.3M on share buybacks and $32.5M on dividends in the twelve months to 31 Mar 2026.

  • Shares outstanding: 13.1M.

  • Trailing P/E: 25.9×; forward P/E: 18.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.54%, paying out 12% of earnings.

  • Chemed Corp. employs 15,811 people — $161K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 3 Sept 2026

Data provided by Twelve Data

Peers

CHE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
CHEChemed Corp.$6.7B
89
PACSPACS Group, Inc.$6.7B
88
UHSUniversal Health Services, Inc.$9.9B
66
LFSTLifestance Health Group, Inc.$5.0B
93
ENSGThe Ensign Group, Inc.$10.0B
65
CONConcentra Group Holdings Parent, Inc.$4.3B
96
DVADaVita, Inc.$12.0B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Chemed Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CHE news & analysis

CHEMED CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Chemed Corporation's Directors and Officers for Breach of Fiduciary Duties – CHE

Business Wire · 3 Sept 2026negative

Scott+Scott Attorneys at Law LLP announced it is investigating whether Chemed Corporation's officers and directors breached their fiduciary duties to the company and whether Chemed and its shareholders have suffered damages as a result. The probe, led by attorney Joseph A. Pettigrew, follows an August 13, 2026 report released by The Capital Forum.

Why it matters — A law firm has launched an investigation into possible breaches of fiduciary duty by Chemed's leadership, which could signal governance concerns for shareholders.

Chemed (CHE) Up 1.7% Since Last Earnings Report: Can It Continue?

Zacks Investment Research · 27 Aug 2026neutral

Chemed reported earnings 30 days ago, and its stock has risen 1.7% since that report. The article examines what may come next for the company's shares.

Why it matters — Chemed watchers would care because the piece assesses the company's stock performance since its latest earnings report and considers what could follow.

OPCH or CHE: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 25 Aug 2026neutral

Zacks Investment Research published a piece comparing Option Care (OPCH) and Chemed (CHE) as value stock opportunities for investors in the Medical - Outpatient and Home Healthcare sector. The article poses the question of which of the two stocks presents the better value opportunity at this time.

Why it matters — CHE watchers would care because the piece evaluates Chemed's value proposition relative to a sector peer, potentially drawing investor attention to the company.

CHEMED CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Chemed Corporation's Directors and Officers for Breach of Fiduciary Duties – CHE

Business Wire · 20 Aug 2026negative

Scott+Scott Attorneys at Law LLP has launched an investigation into whether Chemed Corporation's officers and directors breached their fiduciary duties, following a report by The Capital Forum released on August 13, 2026. The law firm is examining whether Chemed and its shareholders have suffered damages as a result.

Why it matters — A shareholder-focused investigation into potential fiduciary breaches by Chemed's leadership could signal legal and governance concerns for the company.

Chemed Corporation Declares Quarterly Dividend of 70 Cents

GlobeNewsWire · 6 Aug 2026positive

Chemed Corporation's board declared a quarterly cash dividend of 70 cents per share, payable September 3, 2026, to shareholders of record as of August 17, 2026. The dividend represents a 10-cent, or 17%, increase over the 60-cent dividend paid in June 2026.

Why it matters — A CHE watcher would note the higher quarterly payout as a sign of the company's ongoing commitment to returning capital to shareholders.

FAQ

Frequently asked questions about CHE stock

What is the CHE stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Chemed Corp. have a median 12-month price target of $549, with estimates ranging from $520 to $590. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CHE stock a buy right now?

Of the 4 analysts covering Chemed Corp., 1 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Chemed Corp. 89 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CHE?

As at 2 Sept 2026, Chemed Corp. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (96 of 100).

Will CHE stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +4.7% from the last close, and Ticker Nerd's factor model ranks Chemed Corp. 89 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CHE stock forecast for 2030?

No analyst covering Chemed Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CHE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $520 to $590 over the next 12 months.

How has CHE stock performed over the past year?

Chemed Corp. returned +14.7% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Chemed Corp. do?

Chemed Corp. is a diversified holding company focused on healthcare and essential home services.

What is the latest news on CHE?

The most recent item we track (Business Wire, 3 Sept 2026): "CHEMED CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Chemed Corporation's Directors and Officers for Breach of Fiduciary Duties – CHE". Scott+Scott Attorneys at Law LLP announced it is investigating whether Chemed Corporation's officers and directors breached their fiduciary duties to the company and whether Chemed and its shareholders have suffered damages as a result. The probe, led by attorney Joseph A. Pettigrew, follows an August 13, 2026 report released by The Capital Forum.

Company

About Chemed Corp.

Chemed Corp. is a diversified holding company focused on healthcare and essential home services. Its operations are organized around two core segments: VITAS, which provides hospice and palliative care through a multidisciplinary network of clinicians and caregivers, and Roto-Rooter, which delivers plumbing, drain cleaning, excavation, and water restoration services to residential and commercial customers. Chemed Corp. serves patients, families, homeowners, businesses, and property managers across the United States, combining end-of-life care services with maintenance and emergency repair solutions. The company’s business model centers on operating specialized service brands with distinct customer needs and market dynamics, giving it a unique position in both healthcare services and home repair markets.

CEO Mr. Kevin J. McNamara · 15,811 employees · United States · https://www.chemed.com